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Abstract
Background: The association between fetal exposure to major radiodiagnostic testing in pregnancy—computed
tomography (CT) and radionuclide imaging—and the risk of childhood cancer is not established.
Methods and Findings: We completed a population-based study of 1.8 million maternal-child pairs in the province of
Ontario, from 1991 to 2008. We used Ontario’s universal health care–linked administrative databases to identify all term
obstetrical deliveries and newborn records, inpatient and outpatient major radiodiagnostic services, as well as all children
with a malignancy after birth. There were 5,590 mothers exposed to major radiodiagnostic testing in pregnancy (3.0 per
1,000) and 1,829,927 mothers not exposed. The rate of radiodiagnostic testing increased from 1.1 to 6.3 per 1,000
pregnancies over the study period; about 73% of tests were CT scans. After a median duration of follow-up of 8.9 years, four
childhood cancers arose in the exposed group (1.13 per 10,000 person-years) and 2,539 cancers in the unexposed group
(1.56 per 10,000 person-years), a crude hazard ratio of 0.69 (95% confidence interval 0.26–1.82). After adjusting for maternal
age, income quintile, urban status, and maternal cancer, as well as infant sex, chromosomal or congenital anomalies, and
major radiodiagnostic test exposure after birth, the risk was essentially unchanged (hazard ratio 0.68, 95% confidence
interval 0.25–1.80).
Conclusions: Although major radiodiagnostic testing is now performed in about 1 in 160 pregnancies in Ontario, the
absolute annual risk of childhood malignancy following exposure in utero remains about 1 in 10,000. Since the upper
confidence limit of the relative risk of malignancy may be as high as 1.8 times that of an unexposed pregnancy, we cannot
exclude the possibility that fetal exposure to CT or radionuclide imaging is carcinogenic.
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Cancer remains the second leading cause of hospitalization and
death among children aged 14 y and younger in industrialized
nations [1–3]. Fewer than 10% of childhood cancers are
attributable to a genetic predisposition [4]. With the exception
of a few known risk factors, including exposure to ionizing
radiation in utero and after birth [5,6], the etiology of most
childhood cancer remains unknown.
There has been a substantial increase in the utilization of
computed tomography (CT) and radionuclide (nuclear medicine)
radiodiagnostic procedures, making them a common source of
radiation to patients [7–9]. Since these tests are often ordered
under emergency circumstances [10], inadvertent exposure in
early pregnancy may occur, since half of all pregnancies are
unplanned [11].
There may be an association between exposure to ionizing
radiation in pregnancy and childhood cancer, yet, the supporting
data are somewhat conflicting. For example, studies of cancer
incidence following intrauterine exposure to the atomic bomb are
inconsistent [12–14], as have some [15], but not all [16–18] studies
examining maternal exposure to plain radiographs in pregnancy.
Less is known about the risk related to major radiodiagnostic tests,
such as CT and radionuclide imaging, both of which expose the
fetus to considerably higher doses of radiation than plain
radiographs administered at the same anatomical level [19,20].
We studied women exposed to major radiodiagnostic tests in
pregnancy in an effort to provide clinicians and mothers with
better estimates of the risk of pediatric malignancy in their
offspring.
Methods
Study Design
We completed a retrospective population-based cohort study of
women who delivered a liveborn infant in Ontario between April
1, 1992 and March 31, 2008. The study was approved by the
Ethics Review Board of Sunnybrook Health Sciences Centre.
Participants
We included singleton and multifetal pregnancies, and for the
latter we included the first infant birth record to avoid multiple
counts per pregnancy. We included maternal-infant pairs compris-
ing term liveborn infants who survived more than 30 d after date of
birth. For three reasons, we restricted the sample to term infants
$37 wk gestation, and who weighed at least 2,500 g at birth: First,
preterm infants are commonly exposed to radiodiagnostic imaging
procedures in hospital [21,22], which could potentially contaminate
the studied effect of prenatal exposure. Second, since term infants
represent 94% of all livebirths [23], our findings would remain
applicable to most pregnancies. We defined term infants by actual
gestationalage from2002onward,thetime inwhichitwascaptured
in our dataset; before 2002, term status was based on the absence of
any diagnostic codes for prematurity according to the International
Classification of Diseases, 9th (ICD-9) and 10th (ICD-10CA)
revisions (Table S1). Thus, limiting our cohort to term infants
enabled us to better estimate the gestational age of fetal exposure to
a major radiodiagnostic test prior to the year 2002.
Exposure and Outcome
The study exposure was CT or radionuclide imaging in an
index pregnancy, up to 2 d before the day of delivery (to maximize
the likelihood that the fetus was in utero). Prior to the year 2002,
gestational age at birth was not recorded in our databases, so the
estimated gestational age at exposure was calculated by subtract-
ing 37 wk from the delivery date. This approach has a reported
sensitivity of 90% and specificity of 99% [24]. From 2002 onward,
we used the recorded gestational age at delivery to determine the
timing of exposure to a radiodiagnostic test.
The main study outcome was a confirmed diagnosis of any
pediatric malignancy in a child born in the index pregnancy at any
time 30 d or more after his/her birth. This 30-d interval was used
to exclude infants who died from major morbidity, such as
neonatal sepsis or severe anomalies.
Database Sources
We used anonymized databases for the entire province of
Ontario, where universal health care, including prenatal care and
radiodiagnostic testing, is available to all residents. Databases were
linked using unique encrypted identifiers, which enabled us to link
radiation exposure in an index pregnancy to a diagnosed
malignancy in a child.
Individual obstetrical deliveries were identified in the Canadian
Institute for Health Information Discharge Abstract Database
(DAD). The DAD contains age and sex, dates of admission, and
up to 16 diagnoses coded by ICD-9 up to March 31, 2002, and up
to 25 diagnoses coded by ICD-10-CA thereafter. Up to 2002,
inpatient admission records for mothers and newborns are
probabilistically linked using delivery/birth dates in the same
hospital, same residential postal codes, and diagnostic information
to create each mother-child pair. This approach leads to successful
matching in 95% of cases. Validation studies of similar maternal-
newborn linkages have shown that this approach yields high
degrees of successful matching, with a sensitivity of about 95% and
a specificity of nearly 90% [25–27]. In a Canadian study linking
newborn birth records and infant death records, over 99% of
records were successfully linked [28]. Starting in the fiscal year
2002/2003, a common identifying number between a delivering
mother’s chart number and her newborn’s chart number
permitted a deterministic linkage between the two from 2002
and onward. The DAD was also used to define study covariates
(Table S1).
For the study exposure—a major radiodiagnostic test performed
on the mother up to one day before her delivery date—we used
the Ontario Health Insurance Plan (OHIP) database, which
captures all billing information for physician services, including
inpatient and outpatient major radiodiagnostic services [29,30]. In
an audit of a representative sample of 11,824 outpatient CT scans
and 11,867 outpatient magnetic resonance imaging (MRI) scans
identified from 29 randomly selected hospitals across Ontario,
95% of the procedures studied in the chart audit had a
corresponding claim in the OHIP database, indicating that these
administrative databases have high accuracy in identifying
imaging procedures [30]. In the current study, major radio-
diagnostic testing included all forms of CT and radionuclide
imaging (Table S2). Because the OHIP database does not capture
all billings for inpatient radionuclide imaging before 2006, the
DAD was used to identify inpatient radionuclide tests performed
throughout the study period (Table S2).
For the study outcome—pediatric malignancy—each child
record was linked to the Ontario Cancer Registry (OCR), a
computerized database of information on all Ontario residents
who have been newly diagnosed with cancer [31]. All new cases of
cancer, except for nonmelanoma skin cancer, are registered, and
about 80% have the tissue pathological diagnosis recorded within
the OCR. Validation studies have shown the OCR to be effective
in ascertaining cancer cases in the province, with a sensitivity of
98% [32]. Close to 400,000 records are submitted to the OCR
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Incident cases of pediatric malignancy were captured according to
a date of diagnosis between May 1, 1991 (a minimum of 30 d after
the earliest birth in the study cohort) and March 31, 2009 (a
maximum of 18 y after the earliest birth in the cohort).
Mortality data were retrieved from the Registered Persons
Database (RPDB), which contains demographic information for all
OHIP-eligible individuals. Income quintile and rurality were
defined using Statistics Canada census data. The OHIP database
was also used to identify outpatient claims for prenatal ultra-
sonography at any point in pregnancy (Table S2) [33].
Statistical Analysis
We measured the absolute number of radiodiagnostic tests
performed in each livebirth pregnancy in a given year and
calculated the annual test rate per 1,000 livebirths, from 1992 to
2008. Changes over time in the rates for radionuclide tests, CT,
and both were analyzed using a Cochran-Armitage test for trend.
Time-to-event analyses were conducted using Cox proportional
hazards regression models, to derive a hazard ratio (HR) and 95%
confidence interval (CI) for pediatric malignancy among children
born to mothers exposed versus not exposed to major radio-
diagnostic imaging in pregnancy.
The period of observation for each child started 31 d after birth,
to ensure that he or she survived long enough to develop, or to be
diagnosed with, a malignancy. A child was censored (i.e.,
determined to have not had a study outcome event) at the point
in time in which he or she either reached the end of the period of
March 31, 2009 without having experienced a study outcome
event or died during the period of study. While emigration from
the province could not be ascertained, the annual rate is less
than 1% (http://www.statcan.gc.ca/pub/75-001-x/2008110/t/
10711/5800473-eng.htm); such persons were classified as being
event-free up to March 31, 2009.
The HR was adjusted for maternal age at delivery (in years),
income quintile, urban status, and maternal cancer diagnosed in
the index pregnancy or up to 6 mo thereafter, as well as infant sex,
a chromosomal or congenital anomaly documented at the time of
birth or up to 365 d thereafter (present or absent), and exposure to
CT or radionuclide imaging (as present or absent) starting 31 d
after birth and up to 365 d before either the date that he/she
experienced a study outcome event or the date that he/she was
censored. The latter considered postnatal exposure to the same
ionizing radiation sources as in pregnancy. Information about
maternal parity, prior pregnancy loss, smoking, and medication
use were not available.
All p-values were two-sided, at a significance level of 0.05. All
statistical analyses were performed using SAS for UNIX, Version
9.1 (SAS Institute).
Results
There were 2,018,924 maternal-child pairs initially generated,
of which 183,442 (9.1%) were excluded for the following reasons:
newborn weight ,2,500 g or .6,000 g (n=113,718); preterm
delivery ,37 wk gestation (n=50,881); multiple births subsequent
to the first birth (n=10,116); maternal age ,16 y or .50 y
(n=4,091); nonresident of Ontario (n=2,310); infant death #30 d
after birth (n=1,514); stillbirth (n=780); extreme post-term birth
.43 wk gestation (n=29); and incorrect coding of birth date
(n=3). Among those excluded, the rate of stillbirth was not
significantly different among mothers exposed (0.65%) and not
exposed (0.84%) to major radiodiagnostic testing in pregnancy.
Among all mothers exposed to major radiodiagnostic testing in
pregnancy, the characteristics of those who were included and
excluded are listed in Table S3.
The final cohort comprised 1,835,517 maternal-child pairs. The
demographic characteristics of the 5,590 mothers exposed to
major radiodiagnostic testing in pregnancy were generally similar
to the unexposed cohort of 1,829,927 women (Table 1). However,
the rate of diagnosed cancer during or soon after pregnancy was
higher in the exposed mothers (0.63% versus 0.050%), as was the
rate of early prenatal ultrasonography (33.0% versus 19.0%).
Among the liveborn infants of mothers exposed and not exposed
to a major radiodiagnostic test, just under half were female, and the
mean (standard deviation [SD]) gestational ages at birth were 39.1
(1.2) and 39.3 (1.1) wk, respectively (Table 1). The rates of
chromosomal (0.13% versus 0.11%) and congenital (3.9% versus
3.7%) anomalies were about the same in both groups, as were the
rates of CT or radionuclide imaging after birth (4.4% versus 4.4%).
The overall rate of exposure to major radiodiagnostic testing in
pregnancy was 3.0 per 1,000, which increased significantly over
time, peaking at 6.3 per 1,000 livebirth pregnancies in 2008 (trend
p,0.001) (Figure 1). Exposure to major radiodiagnostic testing in
pregnancy occurred at an estimated mean (SD) gestational age of
15.7 (12.8) wk, and about half were completed before 14 wk
gestation (Table 1). 15% of women had two or more tests
performed in pregnancy. About 73% of all major radiodiagnostic
tests were CT scans, of which 68% were of an extremity or head,
nearly 10% of the thorax, and 22.6% of the abdomen, spine, or
pelvis (Table 1).
There were 35,487 and 16,326,410 persons-years of follow-up
in the exposed and unexposed groups, respectively. Among the
entire cohort of 1,835,517 children, the median (interquartile
range [IQR]) duration of follow-up was 8.91 (4.83–13.00) y. A
total of 1,015,789 (55.3%) children were followed to age 8 y,
797,940 (43.5%) to age 10 y, 573,445 (31.2%) to age 12 y, and
341,432 (18.6%) to age 14 y.
A total of four childhood cancers occurred in the exposed group
(1.13 per 10,000 person-years) and 2,539 cancers in the unexposed
group (1.56 per 10,000 person-years), corresponding to a crude
HR of 0.69 (95% CI 0.26–1.82) (Figure 2; Table 2). After adjusting
for potential confounders, the risk was not significantly higher
among exposed versus unexposed maternal-child pairs (HR 0.68,
95% CI 0.25–1.80). Upon adding into the sample previously
excluded infants at extremes of gestational age and birthweight,
the crude (0.71, 95% CI 0.29–1.70) and adjusted (0.69, 95% CI
0.29–1.66) HR remained unchanged. We could not specify the
types of cancers arising in the exposed group because of a strict
privacy policy at our institution about the reporting of specific
information for cell sizes under the number 5.
Discussion
About 1 in 160 term pregnancies now appear to be exposed to a
major radiodiagnostic test. The offspring of women exposed to
major radiodiagnostic testing in pregnancy do not appear to be at
higher risk of childhood malignancy than the children of
unexposed mothers. Moreover, the overall prevalence of pediatric
malignancy following exposure to CT or radionuclide imaging in
pregnancy was under 0.07%, an incidence rate of 1.13 per 10,000
person-years.
Study Strengths and Limitations
Among those exposed to major radiodiagnostic testing, totaling
nearly 5,600 pregnancies and 35,000 persons-years of follow-up,
just four cases of childhood malignancy were identified. The
incidence rate of 1.56 cancers per 10,000 person-years, based on
Radiodiagnostic Imaging in Pregnancy
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Characteristic
a Major Radiodiagnostic Test in Pregnancy
Exposed (n=5,590) Unexposed (n=1,829,927)
Maternal
Mean (SD) age at delivery, y 29.0 (5.7) 29.3 (5.4)
Age at delivery, y
16–19 168 (3.0) 47,729 (2.6)
20–24 1,013 (18.1) 273,835 (15.0)
25–29 1,667 (29.8) 558,566 (30.5)
30–34 1,662 (29.7) 607,798 (33.2)
35–39 784 (14.0) 265,545 (14.5)
40–44 170 (3.0) 43,674 (2.4)
45–50 8 (0.14) 1,464 (0.080)
Income quintile (Q)
Q1 (lowest) 1,435 (25.7) 416,705 (22.8)
Q5 (highest) 784 (14.0) 302,374 (16.5)
Urban residence 4,737 (84.7) 1,528,253 (83.5)
Mean (SD) length of stay at delivery hospitalization, d 2.5 (2.2) 2.3 (1.6)
Cancer diagnosis in pregnancy or #6 mo after delivery 35 (0.63) 1,004 (0.050)
Prenatal ultrasonography any time in pregnancy 4,956 (88.7) 1,452,376 (79.4)
Prenatal ultrasonography ,16 wk gestation 1,845 (33.0) 348,104 (19.0)
Major radiodiagnostic testing in pregnancy
Estimated mean (SD) gestational age at exposure, wk 15.7 (12.8) —
Estimated gestational age at exposure, wk
0–14 2,866 (51.3) —
$15 2,724 (48.7) —
Mean (SD) number of major radiodiagnostic tests 1.20 (0.59) —
Number of major radiodiagnostic tests
1 4,756 (85.1) —
$2 834 (14.9) —
Major radiodiagnostic test type —
Radionuclide test
b 1,527 (27.3)
CT scan 4,088 (73.1) —
Anatomical location of the CT scan —
Extremity or head 2,762 (67.6) —
Thorax 405 (9.9) —
Abdomen or spine 448 (11.0) —
Pelvis 473 (11.6) —
Liveborn infant
Female sex 2,745 (49.1) 891,969 (48.7)
Mean (SD) gestational age at birth, wk
c 39.1 (1.2) 39.3 (1.1)
Mean (SD) birthweight, g 3,476 (466) 3,497 (462)
Any chromosomal anomaly 7 (0.13) 2,013 (0.11)
Any congenital anomaly 220 (3.9) 67,284 (3.7)
Any major radiodiagnostic test exposure after birth 244 (4.4) 80,348 (4.4)
aAll data are presented as a number (%) unless otherwise indicated.
bVentilation-perfusion lung scan (89.4%) or thyroid scan (10.6%).
cDetermined using data from April 1, 2002 onward.
doi:10.1371/journal.pmed.1000337.t001
Radiodiagnostic Imaging in Pregnancy
PLoS Medicine | www.plosmedicine.org 4 September 2010 | Volume 7 | Issue 9 | e1000337Figure 1. Annual rate of major radiodiagnostic testing in pregnancy in Ontario over time. Data are presented for radionuclide testing
(lower solid line), CT scan (upper dashed line), and both (solid bars with total number per year).
doi:10.1371/journal.pmed.1000337.g001
Figure 2. Risk of childhood cancer in the offspring of women exposed (lower solid) and not exposed (upper dashed) to a major
radiodiagnostic test in pregnancy.
doi:10.1371/journal.pmed.1000337.g002
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highly concordant with population studies from Canada, the
United States, Ireland, and Europe [1–3]. Post hoc, considering
the number of participants enrolled in the current study, at a
conventional p-value of 0.05, we had just under 20% statistical
power to detect the observed difference of 0.40 per 10,000 person-
years in the incidence rate of childhood malignancy between
exposed and unexposed mothers. To achieve a power of 80%,
approximately 60 and 19,613 cancers would be needed in the
exposed and unexposed groups, respectively—about eight times
higher than the current number of events. That so few cases of
childhood malignancy were identified among the exposed is a
testament to the difficulty of conducting research in this area, and
why previous data may have been lacking. Nonetheless, the wide
confidence limits of our relative risk estimates do not exclude the
possibility that fetal exposure to CT or radionuclide imaging in
pregnancy is carcinogenic, ranging from as low as one-quarter, to
as high as 1.8 times, that of an unexposed pregnancy.
We did not include women who had a radiodiagnostic test in a
pregnancy that ended in a spontaneous or therapeutic termination
before 20-wk gestation. However, this study’s focus was on
childhood malignancy after 30 d of life, rather than on pregnancy
loss, and it is unlikely that including that group of women would
have systematically biased the association between the study
exposure and outcome. Moreover, the rates of stillbirth after
20 wk among excluded women exposed (0.65%) and not exposed
(0.84%) to major radiodiagnostic testing in pregnancy did not
differ significantly. By limiting our sample to term deliveries
between 37 and 43 wk gestation and restricting the period of
exposure up to 2 d before a woman’s date of delivery, we
improved the accuracy of our determination of the timing of
exposure to radiodiagnostic testing. At the same time, our findings
may not apply to preterm infants, who both have higher rates of
congenital and chromosomal anomalies, as well as major radio-
diagnostic testing soon after birth (Table S3) [21,22].
We did not have on record whether a woman’s pregnancy was
known at the time of exposure, or if she received lead apron
shielding of the abdominal-pelvic area. Assuming that shielding
occurred in most cases, as is routine practice, then this may partly
explain the low rate of childhood malignancy in the exposed
group. Moreover, two-thirds of CT scans were of an extremity or
head, with the remaining sites in closer proximity to the fetus, but
only 23% were of the abdomen, spine, or pelvis. Hence, much of
our CT data reflects ‘‘low-risk’’ scans, in terms of fetal radiation
exposure.
We also do not possess information about the generation(s) of
CT scans that were used, or the measured dose of ionizing
radiation that a woman and her fetus were exposed to. The cited
average effective maternal radiation dose of CT of the head or
neck is about 2 millisievert (mSv); for a CT of the chest, spine,
abdomen, or pelvis it ranges from 6 to 8 mSv [9,34]; and for a
ventilation-perfusion lung scan it is about 2.5 mSv [34]. While
these doses are between 10 to 100 times more than that of an
equivalent single plain X-ray [34], the effective radiation dose to
the fetus remains lower than that to the mother [18,35]. The rate
of major radiodiagnostic testing in pregnancy in our study is
certainly lower than when plain X-rays were performed in
pregnancy for maternal pelvimetry [36]. In the era of the current
study, pelvimetry was not routine, but we would have missed plain
X-rays performed for other reasons.
Mothers, as well as clinicians of all types—internists, surgeons,
radiologists, obstetricians and midwives, pediatricians, and family
and emergency medicine physicians—need data to better estimate
the risk of exposure to radiodiagnostic testing in pregnancy. Our
findings, though statistically underpowered, inform this process in
a manner that has been lacking to date, especially using
population-based data over a long period of follow-up, and within
a health care system that provides universal coverage of
radiological testing and health care.
Clinical Implications
Our findings can help inform clinicians and mothers about the
risk of childhood malignancy following major radiodiagnostic
testing in pregnancy. First, the absolute risk appears to be low
(about 0.07% or 1 per 10,000 person-years), while the relative risk
is not statistically significantly higher than unexposed controls,
notwithstanding the wide confidence limits. However potentially
small that risk may be, beta hCG testing should continue to be
done in all potentially pregnant women before undergoing major
radiodiagnostic testing, and lead apron shielding used in all
women of reproductive age, whether or not pregnant [6,37].
Furthermore, nonradiation-emitting imaging (e.g., MRI and
ultrasonography) should be considered first, when appropriate.
Some pregnant women will nevertheless be faced with the
decision to undergo CT or nuclear imaging because the test is
clinically warranted. Unfortunately, some health care providers
may be unwilling to counsel a woman about the related fetal risks
or may provide misinformation [37,38]. This issue seems more
pressing than ever, given that we and others [9] have noted that
CT testing is on the rise, and has become the mainstay for the
investigation of pulmonary embolism [39], stroke [40], appendi-
citis [41], and other common conditions encountered in
emergency situations [10]. Both physiological and anatomical
changes in pregnancy may obscure the clinical diagnosis of
pulmonary embolism [42], for example, such that CT or
radionuclide testing may be especially warranted. Delaying the
diagnosis of such conditions may postpone therapy, in turn,
jeopardizing both mother and child [43].
Table 2. Risk of childhood malignancy in the offspring of women exposed to major radiodiagnostic testing in pregnancy
compared to unexposed women.
Major Radiodiagnostic Test Exposure in Pregnancy
Exposed (n=5,590) Unexposed (n=1,829,927) HR (95% CI)
n events (%)
Incidence rate per 10,000
person-years n events (%)
Incidence rate per
10,000 person-years Crude Adjusted
a
4 (0.072) 1.13 2,539 (0.14) 1.56 0.69 (0.26–1.82) 0.68 (0.25–1.80)
aAdjusted for maternal age at delivery (continuous in years), income quintile, urban status, and diagnosed maternal cancer in the index pregnancy and up to 6 mo
thereafter, as well as infant sex, a chromosomal or congenital anomaly, and exposure to a major radiodiagnostic test exposure after birth.
doi:10.1371/journal.pmed.1000337.t002
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should be carried out, along with brief counseling [37]. The latter
will hopefully lessen the level of anxiety experienced by an
expectant mother (and her family), not only at the time of illness,
but after her child is born.
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Background In industrialized countries, childhood cancer
(any form of cancer in a child aged 14 years or under)
remains a major cause of death. With the exception of a few
known risk factors, such as acquired genetic predisposition
to cancer, which accounts for about 10% of all childhood
cancers, the etiology of most childhood cancer remains
unknown. There is thought to be an association between
exposure to ionizing radiation in pregnancy and the sub-
sequent risk of development of cancer in the exposed
mother’s child, but the evidence base to support this
association is conflicting. For example, studies examining
maternal exposure to plain radiographs in pregnancy and
subsequent childhood cancer are inconsistent. Furthermore,
although their use has dramatically increased over the past
two decades, little is known about the cancer risk related to
certain types of radiodiagnostic tests, such as CT and
radionuclide imaging, both of which expose the fetus to
considerably higher doses of radiation than plain radio-
graphs administered at the same anatomical level.
Why Was This Study Done? Many women could be
exposed to major radiodiagnostic tests, such as those used in
emergency situations, before they are aware that they are
pregnant, as almost 50% of pregnancies are unplanned. This
situation means that it is important to determine the
subsequent cancer risk to any child exposed to maternal
radiodiagnostic tests before birth.
What Did the Researchers Do and Find? The researchers
conducted a retrospective population-based cohort study of
women who delivered a live infant in Ontario, Canada
between April 1, 1992 and March 31, 2008. The basis of the
research was an anonymized database for the whole
province of Ontario, where universal health care, including
prenatal care and radiodiagnostic testing, is available to all
residents. Database characteristics allowed the researchers to
link maternal radiation exposure (a major radiodiagnostic
test performed on the mother up to one day before her
delivery date) in a specific (index) pregnancy to a subsequent
malignancy in the child. After birth, maternal-infant pairs
were only followed up if the infant was delivered at term,
weighed 2,500 g or more, and survived for at least 30 days.
The researchers were able to follow up 1,835,517 maternal-
child pairs. The overall rate of exposure to major radio-
diagnostic testing in pregnancy was 3.0 per 1,000 and
occurred at an estimated mean gestational age of 15.7
weeks. A total of four childhood cancers occurred in
the exposed group and 2,539 cancers in the unexposed
group corresponding to a crude hazard ratio of 0.69, which
did not significantly change after adjustments were made for
potential confounding factors, such as maternal age, sex, and
the presence of any chromosomal or congenital anomalies in
the infant. The overall prevalence of childhood cancer
following exposure to CT or radionuclide imaging in
pregnancy is under 0.07%, giving an incidence rate of 1.13
per 10,000 person-years.
What Do These Findings Mean? These findings can help
inform clinicians and mothers about the risk of childhood
malignancy following major radiodiagnostic testing in preg-
nancy. The absolute risk appears to be low, while the relative
risk is not materially higher than that of unexposed controls.
However, as the upper confidence limit of the relative risk of
malignancy may be a maximum of 1.8 times that of an
unexposed pregnancy, the possibility that fetal exposure
to CT or radionuclide imaging is carcinogenic cannot be
excluded. Because this finding means that a very slight risk
may exist, beta hCG testing should continue to be done in all
potentially pregnant women before undergoing major
radiodiagnostic testing, and lead apron shielding used in
all women of reproductive age, whether or not known to be
pregnant. In addition, nonradiation-emitting imaging, such
as MRI and ultrasonography, should be considered first,
when clinically appropriate. However, some pregnant
women will still be faced with the decision to undergo CT
or nuclear imaging because the test is clinically warranted.
The findings of this study suggest that when clinically
indicated, major radiodiagnostic testing in pregnancy should
be performed, along with brief counseling to help lessen the
anxiety experienced by an expectant mother before and
after the birth of her child.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000337.
N For information for patients and caregivers on radio-
diagnostic testing, see The Royal College of Radiologists
N The National Cancer Institute provides information about
childhood cancer
N CureSearch for Children’s Cancer provides additional
information about research into childhood cancer
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